Jeffrey A. Engelman, Ph.D. - Publications

2000 Yeshiva University, New York, NY, United States 
Molecular Biology, Pharmacology

166 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Bialucha CU, Collins SD, Li X, Saxena P, Zhang X, Dürr C, LaFont B, Prieur P, Shim Y, Mosher R, Lee D, Ostrom L, Hu T, Bilic S, Liric Rajlic I, ... ... Engelman JA, et al. Discovery and Optimization of HKT288, a Cadherin-6 Targeting ADC for the Treatment of Ovarian and Renal Cancer. Cancer Discovery. PMID 28526733 DOI: 10.1158/2159-8290.CD-16-1414  0.36
2016 Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ. Acquired Resistance to Crizotinib in Non-small Cell Lung Cancer with MET exon 14 skipping. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27343442 DOI: 10.1016/j.jtho.2016.06.013  0.6
2016 Shaw AT, Engelman JA. Crizotinib Resensitization by Compound Mutation. The New England Journal of Medicine. 374: 1790-1. PMID 27144862 DOI: 10.1056/NEJMc1601366  0.6
2016 Heist RS, Shim HS, Gingipally S, Mino-Kenudson M, Le L, Gainor JF, Zheng Z, Aryee M, Xia J, Jia P, Jin H, Zhao Z, Pao W, Engelman JA, Iafrate AJ. MET Exon 14 Skipping in Non-Small Cell Lung Cancer. The Oncologist. PMID 27022036 DOI: 10.1634/theoncologist.2015-0510  0.6
2016 Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, ... ... Engelman JA, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications. 7: 10501. PMID 26883990 DOI: 10.1038/ncomms10501  0.6
2016 Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, ... ... Engelman JA, et al. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. Ebiomedicine. 3: 54-66. PMID 26870817 DOI: 10.1016/j.ebiom.2015.12.009  0.6
2016 Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, ... ... Engelman JA, et al. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell. 29: 159-72. PMID 26859456 DOI: 10.1016/j.ccell.2016.01.002  0.6
2016 Breitkopf SB, Yang X, Begley MJ, Kulkarni M, Chiu YH, Turke AB, Lauriol J, Yuan M, Qi J, Engelman JA, Hong P, Kontaridis MI, Cantley LC, Perrimon N, Asara JM. A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2. Scientific Reports. 6: 20471. PMID 26839216 DOI: 10.1038/srep20471  0.6
2016 Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HC, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, ... ... Engelman JA, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine. PMID 26828195 DOI: 10.1038/nm.4040  0.6
2016 Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, Timple N, Vaillancourt MT, Culazzo Pferdekamper A, Lockerman EL, Li C, Anderson J, Costa C, Liao D, Murphy E, ... ... Engelman JA, et al. EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Research. PMID 26825170 DOI: 10.1158/0008-5472.CAN-15-2581  0.6
2016 Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda DG, ... ... Engelman JA, et al. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. Journal of the National Cancer Institute. 108. PMID 26547932 DOI: 10.1093/jnci/djv313  0.6
2015 Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, ... ... Engelman JA, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. The New England Journal of Medicine. PMID 26698910 DOI: 10.1056/NEJMoa1508887  0.6
2015 Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Janne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu H, ... ... Engelman JA, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446944 DOI: 10.1158/1078-0432.CCR-15-1031  0.6
2015 Engelman JA, Oser MG, Niederst MJ, Sequist LV. Transformation from NSCLC to SCLC: when did it happen? - Authors' reply. The Lancet. Oncology. 16: e309-10. PMID 26149875 DOI: 10.1016/S1470-2045(15)00058-3  0.6
2015 Duda DG, Heist RS, Sahani DV, Stylianopoulos T, Engelman JA, Jain RK. Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 112: E3454. PMID 26080434 DOI: 10.1073/pnas.1507225112  0.6
2015 Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3924-33. PMID 25964297 DOI: 10.1158/1078-0432.CCR-15-0560  0.6
2015 Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, ... ... Engelman JA, et al. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery. 5: 713-22. PMID 25934077 DOI: 10.1158/2159-8290.CD-15-0399  0.6
2015 O'Brien TD, Jia P, Xia J, Saxena U, Jin H, Vuong H, Kim P, Wang Q, Aryee MJ, Mino-Kenudson M, Engelman JA, Le LP, Iafrate AJ, Heist RS, Pao W, et al. Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods (San Diego, Calif.). 83: 118-27. PMID 25913717 DOI: 10.1016/j.ymeth.2015.04.016  0.6
2015 Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. The Lancet. Oncology. 16: e165-72. PMID 25846096 DOI: 10.1016/S1470-2045(14)71180-5  0.6
2015 Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 27: 397-408. PMID 25759024 DOI: 10.1016/j.ccell.2015.02.005  0.6
2015 Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, ... ... Engelman JA, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications. 6: 6377. PMID 25758528 DOI: 10.1038/ncomms7377  0.6
2015 Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, ... ... Engelman JA, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: E1288-96. PMID 25737542 DOI: 10.1073/pnas.1411848112  0.6
2015 Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2745-52. PMID 25724526 DOI: 10.1158/1078-0432.CCR-14-3009  0.6
2015 Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DA. Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. Elife. 4. PMID 25686219 DOI: 10.7554/eLife.06132  0.6
2015 Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, ... ... Engelman JA, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery. 5: 358-67. PMID 25673644 DOI: 10.1158/2159-8290.CD-14-1518  0.6
2015 Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: 1547-52. PMID 25605928 DOI: 10.1073/pnas.1424024112  0.6
2015 Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell. 27: 97-108. PMID 25544637 DOI: 10.1016/j.ccell.2014.11.007  0.6
2015 Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 166-74. PMID 25351743 DOI: 10.1158/1078-0432.CCR-14-1385  0.6
2015 Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes C, Engelman JA, Bardeesy N. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 396-404. PMID 25348516 DOI: 10.1158/1078-0432.CCR-14-1591  0.6
2014 Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, ... ... Engelman JA, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (New York, N.Y.). 346: 1480-6. PMID 25394791 DOI: 10.1126/science.1254721  0.6
2014 Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5686-96. PMID 25228534 DOI: 10.1158/1078-0432.CCR-14-1511  0.6
2014 Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ. AACR Cancer Progress Report 2014. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: S1-S112. PMID 25228531 DOI: 10.1158/1078-0432.CCR-14-2123  0.6
2014 Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. The New England Journal of Medicine. 370: 2537-9. PMID 24963575 DOI: 10.1056/NEJMc1404894  0.6
2014 Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Research. 74: 3146-56. PMID 24675361 DOI: 10.1158/0008-5472.CAN-13-3728  0.6
2014 Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, ... ... Engelman JA, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discovery. 4: 662-73. PMID 24675041 DOI: 10.1158/2159-8290.CD-13-0846  0.6
2014 Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, ... ... Engelman JA, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. The New England Journal of Medicine. 370: 1189-97. PMID 24670165 DOI: 10.1056/NEJMoa1311107  0.6
2014 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 25: 282-303. PMID 24651011 DOI: 10.1016/j.ccr.2014.02.025  0.6
2014 Ebi H, Faber AC, Engelman JA, Yano S. Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Science. 105: 499-505. PMID 24612015 DOI: 10.1111/cas.12383  0.6
2014 Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I, O'Connell JP, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 120: 1145-54. PMID 24501009 DOI: 10.1002/cncr.28561  0.6
2014 Jänne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P, Felip E. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 316-23. PMID 24496004 DOI: 10.1097/JTO.0000000000000088  0.6
2014 Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, ... ... Engelman JA, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discovery. 4: 452-65. PMID 24444711 DOI: 10.1158/2159-8290.CD-13-0646  0.6
2014 Chen Z, Akbay E, Mikse O, Tupper T, Cheng K, Wang Y, Tan X, Altabef A, Woo SA, Chen L, Reibel JB, Janne PA, Sharpless NE, Engelman JA, Shapiro GI, et al. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1204-11. PMID 24327273 DOI: 10.1158/1078-0432.CCR-13-1733  0.6
2014 Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, ... ... Engelman JA, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discovery. 4: 42-52. PMID 24163374 DOI: 10.1158/2159-8290.CD-13-0315  0.6
2013 Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH, Engelman JA. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the National Academy of Sciences of the United States of America. 110: 21124-9. PMID 24327733 DOI: 10.1073/pnas.1314124110  0.6
2013 Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nature Reviews. Cancer. 13: 772-87. PMID 24132104 DOI: 10.1038/nrc3612  0.6
2013 Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Science Signaling. 6: re6. PMID 24065147 DOI: 10.1126/scisignal.2004652  0.6
2013 Awad MM, Engelman JA, Shaw AT. Acquired resistance to crizotinib from a mutation in CD74-ROS1. The New England Journal of Medicine. 369: 1173. PMID 24047072 DOI: 10.1056/NEJMc1309091  0.6
2013 Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5390-401. PMID 23948973 DOI: 10.1158/1078-0432.CCR-13-1038  0.6
2013 Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, ... ... Engelman JA, et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Science Translational Medicine. 5: 196ra99. PMID 23903756 DOI: 10.1126/scitranslmed.3005747  0.6
2013 Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, ... ... Engelman JA, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Science Translational Medicine. 5: 196ra98. PMID 23903755 DOI: 10.1126/scitranslmed.3005753  0.6
2013 Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4273-81. PMID 23729361 DOI: 10.1158/1078-0432.CCR-13-0318  0.6
2013 Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, ... ... Engelman JA, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. The New England Journal of Medicine. 368: 2395-401. PMID 23724914 DOI: 10.1056/NEJMoa1215530  0.6
2013 Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, ... ... Engelman JA, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discovery. 3: 870-9. PMID 23715154 DOI: 10.1158/2159-8290.CD-13-0015  0.6
2013 Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Research. 73: 3087-96. PMID 23598276 DOI: 10.1158/0008-5472.CAN-12-3256  0.6
2013 Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2688-98. PMID 23549875 DOI: 10.1158/1078-0432.CCR-12-2556  0.6
2013 Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.CCR-12-3173  0.6
2013 Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1105-11. PMID 23401436 DOI: 10.1200/JCO.2012.44.5353  0.6
2013 Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, ... ... Engelman JA, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 23: 121-8. PMID 23245996 DOI: 10.1016/j.ccr.2012.11.007  0.6
2013 Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY, Scagliotti GV. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 59-66. PMID 22887466 DOI: 10.1093/annonc/mds242  0.6
2012 Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, Engelman JA, Iafrate AJ. FGFR1 amplification in squamous cell carcinoma of the lung. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1775-80. PMID 23154548 DOI: 10.1097/JTO.0b013e31826aed28  0.6
2012 Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, ... ... Engelman JA, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proceedings of the National Academy of Sciences of the United States of America. 109: E3119-27. PMID 23071298 DOI: 10.1073/pnas.1216078109  0.6
2012 Faber AC, Ebi H, Costa C, Engelman JA. Apoptosis in targeted therapy responses: the role of BIM. Advances in Pharmacology (San Diego, Calif.). 65: 519-42. PMID 22959036 DOI: 10.1016/B978-0-12-397927-8.00016-6  0.6
2012 Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet. Oncology. 13: 1011-9. PMID 22954507 DOI: 10.1016/S1470-2045(12)70344-3  0.6
2012 Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, ... ... Engelman JA, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America. 109: E2127-33. PMID 22773810 DOI: 10.1073/pnas.1203530109  0.6
2012 Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 924-33. PMID 22722794 DOI: 10.1097/JTO.0b013e31824cc334  0.6
2012 Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, Shimamura T, Wong KK. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Research. 72: 3302-11. PMID 22552292 DOI: 10.1158/0008-5472.CAN-11-3720  0.6
2012 Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Research. 72: 3228-37. PMID 22552284 DOI: 10.1158/0008-5472.CAN-11-3747  0.6
2012 Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, ... ... Engelman JA, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483: 570-5. PMID 22460902 DOI: 10.1038/nature11005  0.6
2012 Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, ... Engelman JA, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discovery. 2: 227-35. PMID 22448344 DOI: 10.1158/2159-8290.CD-11-0341  0.6
2012 Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell. 21: 448.e2. PMID 22439939 DOI: 10.1016/j.ccr.2012.03.007  0.6
2012 Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, ... ... Engelman JA, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 483: 613-7. PMID 22425996 DOI: 10.1038/nature10937  0.6
2012 Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, ... Engelman JA, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Science Translational Medicine. 4: 120ra17. PMID 22277784 DOI: 10.1126/scitranslmed.3003316  0.6
2012 Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, ... ... Engelman JA, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1227-36. PMID 22261808 DOI: 10.1158/1078-0432.CCR-11-2308  0.6
2012 Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, ... ... Engelman JA, et al. ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 863-70. PMID 22215748 DOI: 10.1200/JCO.2011.35.6345  0.6
2012 Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nature Medicine. 18: 74-82. PMID 22157681 DOI: 10.1038/nm.2577  0.6
2011 Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discovery. 1: 608-25. PMID 22586683 DOI: 10.1158/2159-8290.CD-11-0046  0.6
2011 Sequist LV, Muzikansky A, Engelman JA. A new BATTLE in the evolving war on cancer. Cancer Discovery. 1: 14-6. PMID 22586313 DOI: 10.1158/2159-8274.CD-11-0044  0.6
2011 Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, ... ... Engelman JA, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discovery. 1: 352-65. PMID 22145099 DOI: 10.1158/2159-8290.CD-11-0106  0.6
2011 Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, ... ... Engelman JA, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 2616-24. PMID 22071650 DOI: 10.1093/annonc/mdr489  0.6
2011 Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP, Novello S, Eberhardt WE, Crino L, Habben K, Liu L, Jänne PA, Brownstein CM, Reck M. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4574-80. PMID 22025157 DOI: 10.1200/JCO.2011.36.6799  0.6
2011 Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. The Journal of Clinical Investigation. 121: 4311-21. PMID 21985784 DOI: 10.1172/JCI57909  0.6
2011 Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet. Oncology. 12: 1004-12. PMID 21933749 DOI: 10.1016/S1470-2045(11)70232-7  0.6
2011 Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, ... ... Engelman JA, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Science Translational Medicine. 3: 99ra86. PMID 21900593 DOI: 10.1126/scitranslmed.3002442  0.6
2011 Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Research. 71: 5965-75. PMID 21775521 DOI: 10.1158/0008-5472.CAN-11-0445  0.6
2011 Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Research. 71: 5020-9. PMID 21586612 DOI: 10.1158/0008-5472.CAN-11-0908  0.6
2011 Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2: 336-46. PMID 21505228  0.6
2011 Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proceedings of the National Academy of Sciences of the United States of America. 108: 7535-40. PMID 21502504 DOI: 10.1073/pnas.1019559108  0.6
2011 Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, ... ... Engelman JA, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine. 3: 75ra26. PMID 21430269 DOI: 10.1126/scitranslmed.3002003  0.6
2011 Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, Sequist LV. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. The Oncologist. 16: 319-26. PMID 21339258 DOI: 10.1634/theoncologist.2010-0300  0.6
2011 Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman JA. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Research. 71: 1081-91. PMID 21266357 DOI: 10.1158/0008-5472.CAN-10-1623  0.6
2011 Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1131-9. PMID 21220471 DOI: 10.1158/1078-0432.CCR-10-1220  0.6
2010 Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Science Signaling. 3: ra84. PMID 21098728 DOI: 10.1126/scisignal.2001148  0.6
2010 Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, ... Engelman JA, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine. 363: 1693-703. PMID 20979469 DOI: 10.1056/NEJMoa1006448  0.6
2010 Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, ... Engelman JA, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4953-60. PMID 20940188 DOI: 10.1200/JCO.2010.30.8338  0.6
2010 Engelman JA, Cantley LC. Chemoprevention meets glucose control. Cancer Prevention Research (Philadelphia, Pa.). 3: 1049-52. PMID 20810671 DOI: 10.1158/1940-6207.CAPR-10-0178  0.6
2010 Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. British Journal of Cancer. 103: 1025-33. PMID 20808308 DOI: 10.1038/sj.bjc.6605846  0.6
2010 Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology. 12: 1193-9. PMID 20627894 DOI: 10.1093/neuonc/noq076  0.6
2010 Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 Oncogene. 29: 5193-5203. PMID 20581867 DOI: 10.1038/onc.2010.257  0.6
2010 Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M. Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. The New England Journal of Medicine. 362: 2411-9. PMID 20573930 DOI: 10.1056/NEJMcpc1003885  0.6
2010 Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, ... ... Engelman JA, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 17: 547-59. PMID 20541700 DOI: 10.1016/j.ccr.2010.04.026  0.6
2010 Turke AB, Engelman JA. PIKing the right patient. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3523-5. PMID 20538763 DOI: 10.1158/1078-0432.CCR-10-1201  0.6
2010 Yang JY, Chang CJ, Xia W, Wang Y, Wong KK, Engelman JA, Du Y, Andreeff M, Hortobagyi GN, Hung MC. Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Research. 70: 4709-18. PMID 20484037 DOI: 10.1158/0008-5472.CAN-09-4524  0.6
2010 Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. Embo Molecular Medicine. 2: 146-58. PMID 20432502 DOI: 10.1002/emmm.201000070  0.6
2010 Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Research. 70: 2485-94. PMID 20215504 DOI: 10.1158/0008-5472.CAN-09-3145  0.6
2010 Faber AC, Wong KK, Engelman JA. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle (Georgetown, Tex.). 9: 851-2. PMID 20160489  0.6
2010 Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, ... ... Engelman JA, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17: 77-88. PMID 20129249 DOI: 10.1016/j.ccr.2009.11.022  0.6
2010 Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Jänne PA. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Oncogene. 29: 2346-2356. PMID 20118985 DOI: 10.1038/onc.2009.526  0.6
2010 Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1075-83. PMID 20085938 DOI: 10.1200/JCO.2009.25.3641  0.6
2010 Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Current Opinion in Genetics & Development. 20: 87-90. PMID 20006486 DOI: 10.1016/j.gde.2009.11.002  0.6
2010 Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 357-60. PMID 19949011 DOI: 10.1200/JCO.2009.24.7049  0.6
2009 Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proceedings of the National Academy of Sciences of the United States of America. 106: 19503-8. PMID 19850869 DOI: 10.1073/pnas.0905056106  0.6
2009 Engelman JA. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations Nature Reviews Cancer. 9: 550-562. PMID 19629070 DOI: 10.1038/nrc2664  0.6
2009 Sequist LV, Engelman JA, Lynch TJ. Toward noninvasive genomic screening of lung cancer patients Journal of Clinical Oncology. 27: 2589-2591. PMID 19414671 DOI: 10.1200/JCO.2008.20.4875  0.6
2009 Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer Journal of Clinical Oncology. 27: 1477-1484. PMID 19237633 DOI: 10.1200/JCO.2008.18.6544  0.6
2009 Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists Cell Cycle. 8: 18-22. PMID 19106609  0.6
2008 Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Medicine. 14: 1351-6. PMID 19029981 DOI: 10.1038/nm.1890  0.6
2008 Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman J. Modeling oncogene addiction using RNA interference. Proceedings of the National Academy of Sciences of the United States of America. 105: 12480-4. PMID 18711136 DOI: 10.1073/pnas.0803217105  0.6
2008 Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, ... ... Engelman JA, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4275-83. PMID 18594010 DOI: 10.1158/1078-0432.CCR-08-0168  0.6
2008 Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of Clinical Investigation. 118: 2609-19. PMID 18568074 DOI: 10.1172/JCI34588  0.6
2008 Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, et al. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge conference assessing opportunities for combination therapy Journal of Thoracic Oncology. 3. PMID 18520291 DOI: 10.1097/JTO.0b013e318174e9d3  0.6
2008 Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, ... Engelman JA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2442-9. PMID 18458038 DOI: 10.1200/JCO.2007.14.8494  0.6
2008 Engelman JA, Cantley LC. A Sweet New Role for EGFR in Cancer Cancer Cell. 13: 375-376. PMID 18455118 DOI: 10.1016/j.ccr.2008.04.008  0.6
2008 Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy Current Opinion in Genetics and Development. 18: 73-79. PMID 18325754 DOI: 10.1016/j.gde.2008.01.004  0.6
2008 Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clinical Cancer Research. 14: 2895-2899. DOI: 10.1158/1078-0432.CCR-07-2248  0.6
2007 Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Research. 67: 11924-32. PMID 18089823 DOI: 10.1158/0008-5472.CAN-07-1885  0.6
2007 Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clinical Cancer Research. 13: 4909-4919. PMID 17699871 DOI: 10.1158/1078-0432.CCR-07-0701  0.6
2007 Engelman JA. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer Clinical Cancer Research. 13. PMID 17671156 DOI: 10.1158/1078-0432.CCR-07-0653  0.6
2007 Lee JY, Engelman JA, Cantley LC. PI3K charges ahead Science. 317: 206-207. PMID 17626872 DOI: 10.1126/science.1146073  0.6
2007 Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, ... ... Engelman JA, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 12: 81-93. PMID 17613438 DOI: 10.1016/j.ccr.2007.06.005  0.6
2007 Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, N.Y.). 316: 1039-43. PMID 17463250 DOI: 10.1126/science.1141478  0.6
2006 Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. The Journal of Clinical Investigation. 116: 2695-706. PMID 16906227 DOI: 10.1172/JCI28656  0.6
2006 Engelman JA, Cantley LC, Haber D, Settleman J, Bunn P, Johnson B, Heymach J, Goss G, Lynch T. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors Clinical Cancer Research. 12: 4372s-4376s. PMID 16857813 DOI: 10.1158/1078-0432.CCR-06-0795  0.6
2006 Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews. Genetics. 7: 606-19. PMID 16847462 DOI: 10.1038/nrg1879  0.6
2005 Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Research. 65: 10992-1000. PMID 16322248 DOI: 10.1158/0008-5472.CAN-05-2612  0.6
2005 Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. Journal of the National Cancer Institute. 97: 1185-94. PMID 16106023 DOI: 10.1093/jnci/dji238  0.6
2005 Engelman JA, Jänne PA. Factors predicting response to EGFR tyrosine kinase inhibitors Seminars in Respiratory and Critical Care Medicine. 26: 314-322. PMID 16052433 DOI: 10.1055/s-2005-871990  0.6
2005 Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. The Journal of Cell Biology. 170: 455-64. PMID 16043515 DOI: 10.1083/jcb.200503088  0.6
2005 Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Research. 65: 6401-8. PMID 16024644 DOI: 10.1158/0008-5472.CAN-05-0933  0.6
2005 Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3227-34. PMID 15886310 DOI: 10.1200/JCO.2005.09.985  0.6
2005 Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America. 102: 3788-93. PMID 15731348 DOI: 10.1073/pnas.0409773102  0.6
2005 Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Molecular and Cellular Biology. 25: 1596-607. PMID 15713620 DOI: 10.1128/MCB.25.5.1596-1607.2005  0.6
2002 Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou H, Christ GJ, Edelmann W, Lisanti MP. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Molecular and Cellular Biology. 22: 2329-44. PMID 11884617 DOI: 10.1128/MCB.22.7.2329-2344.2002  0.6
2001 Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H, Kneitz B, Lagaud G, Christ GJ, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. The Journal of Biological Chemistry. 276: 38121-38. PMID 11457855 DOI: 10.1074/jbc.M105408200  0.6
2001 Lee H, Woodman SE, Engelman JA, Volonté D, Galbiati F, Kaufman HL, Lublin DM, Lisanti MP. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). The Journal of Biological Chemistry. 276: 35150-8. PMID 11451957 DOI: 10.1074/jbc.M104530200  0.6
2001 Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, Li M, Hou H, Kneitz B, Edelmann W, Lisanti MP. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. The Journal of Biological Chemistry. 276: 21425-33. PMID 11259414 DOI: 10.1074/jbc.M100828200  0.6
2000 Engelman JA, Berg AH, Lewis RY, Lisanti MP, Scherer PE. Tumor necrosis factor alpha-mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3-L1 adipocytes. Molecular Endocrinology (Baltimore, Md.). 14: 1557-69. PMID 11043572 DOI: 10.1210/mend.14.10.0542  0.6
2000 O'Hagan RC, Schreiber-Agus N, Chen K, David G, Engelman JA, Schwab R, Alland L, Thomson C, Ronning DR, Sacchettini JC, Meltzer P, DePinho RA. Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nature Genetics. 24: 113-9. PMID 10655054 DOI: 10.1038/72761  0.6
1999 Engelman JA, Berg AH, Lewis RY, Lin A, Lisanti MP, Scherer PE. Constitutively active mitogen-activated protein kinase kinase 6 (MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis. The Journal of Biological Chemistry. 274: 35630-8. PMID 10585441 DOI: 10.1074/jbc.274.50.35630  0.6
1999 Engelman JA, Zhang XL, Razani B, Pestell RG, Lisanti MP. p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. The Journal of Biological Chemistry. 274: 32333-41. PMID 10542274 DOI: 10.1074/jbc.274.45.32333  0.6
1999 Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, Lisanti MP. Caveolins, liquid-ordered domains, and signal transduction. Molecular and Cellular Biology. 19: 7289-304. PMID 10523618  0.6
1999 Galbiati F, Volonte D, Engelman JA, Scherer PE, Lisanti MP. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. The Journal of Biological Chemistry. 274: 30315-21. PMID 10514527 DOI: 10.1074/jbc.274.42.30315  0.6
1999 Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, Rodriguez-Boulan E, Peschle C, Lisanti MP. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. The Journal of Biological Chemistry. 274: 25718-25. PMID 10464309 DOI: 10.1074/jbc.274.36.25718  0.6
1999 Engelman JA, Zhang XL, Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. Febs Letters. 448: 221-30. PMID 10218480 DOI: 10.1016/S0014-5793(99)00365-8  0.6
1999 Gómez Lahoz E, Liegeois NJ, Zhang P, Engelman JA, Horner J, Silverman A, Burde R, Roussel MF, Sherr CJ, Elledge SJ, DePinho RA. Cyclin D- and E-dependent kinases and the p57(KIP2) inhibitor: cooperative interactions in vivo. Molecular and Cellular Biology. 19: 353-63. PMID 9858559  0.6
1998 Engelman JA, Zhang X, Galbiati F, Volonte D, Sotgia F, Pestell RG, Minetti C, Scherer PE, Okamoto T, Lisanti MP. Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. American Journal of Human Genetics. 63: 1578-87. PMID 9837809 DOI: 10.1086/302172  0.6
1998 Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. The Journal of Biological Chemistry. 273: 32111-20. PMID 9822687 DOI: 10.1074/jbc.273.48.32111  0.6
1998 Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. The Embo Journal. 17: 6633-48. PMID 9822607 DOI: 10.1093/emboj/17.22.6633  0.6
1998 Engelman JA, Zhang XL, Lisanti MP. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. Febs Letters. 436: 403-10. PMID 9801158 DOI: 10.1016/S0014-5793(98)01134-X  0.6
1998 Schlegel A, Volonte D, Engelman JA, Galbiati F, Mehta P, Zhang XL, Scherer PE, Lisanti MP. Crowded little caves: structure and function of caveolae. Cellular Signalling. 10: 457-63. PMID 9754713 DOI: 10.1016/S0898-6568(98)00007-2  0.6
1998 Li S, Galbiati F, Volonte D, Sargiacomo M, Engelman JA, Das K, Scherer PE, Lisanti MP. Mutational analysis of caveolin-induced vesicle formation. Expression of caveolin-1 recruits caveolin-2 to caveolae membranes. Febs Letters. 434: 127-34. PMID 9738464 DOI: 10.1016/S0014-5793(98)00945-4  0.6
1998 Galbiati F, Volonte D, Gil O, Zanazzi G, Salzer JL, Sargiacomo M, Scherer PE, Engelman JA, Schlegel A, Parenti M, Okamoto T, Lisanti MP. Expression of caveolin-1 and -2 in differentiating PC12 cells and dorsal root ganglion neurons: caveolin-2 is up-regulated in response to cell injury. Proceedings of the National Academy of Sciences of the United States of America. 95: 10257-62. PMID 9707634 DOI: 10.1073/pnas.95.17.10257  0.6
1998 Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, Lisanti MP. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. The Journal of Biological Chemistry. 273: 20448-55. PMID 9685399 DOI: 10.1074/jbc.273.32.20448  0.6
1998 Engelman JA, Zhang XL, Galbiati F, Lisanti MP. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). Febs Letters. 429: 330-6. PMID 9662443 DOI: 10.1016/S0014-5793(98)00619-X  0.6
1998 Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. Febs Letters. 428: 205-11. PMID 9654135 DOI: 10.1016/S0014-5793(98)00470-0  0.6
1997 Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P, Lisanti MP. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. The Journal of Biological Chemistry. 272: 29337-46. PMID 9361015 DOI: 10.1074/jbc.272.46.29337  0.6
1997 Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. The Journal of Biological Chemistry. 272: 16374-81. PMID 9195944 DOI: 10.1074/jbc.272.26.16374  0.6
Show low-probability matches.